Document is current
Any future updates will be listed below
-
Authors
Nanavaty, Mayank A. https://orcid.org/0000-0003-0667-3700
Findl, Oliver
Carones, Francesco
Daya, Sheraz M.
Geerling, Gerd
Kohnen, Thomas https://orcid.org/0000-0002-6933-9585
Kurniawan, Emil D.
Lockington, David
Mertens, Erik L.
Nubile, Mario
Rampat, Radhika
Ribeiro, Filomena
Hajjar Sesé, Aida
Shahnazaryan, David
Yeu, Elizabeth
Dick, H. Burkhard
- License Information
-
More Information
Article History
Received: 24 September 2025
Revised: 15 October 2025
Accepted: 12 November 2025
First Online: 5 December 2025
Competing interests
: EY is an employee and shareholder of Tarsus. All other authors are consultants for Tarsus Pharmaceuticals Inc. and received consultancy fees in relation to this project. Mayank A. Nanavaty is also a consultant to Alcon, Bausch + Lomb, HOYA and Johnson & Johnson & he is a member of Eye Editorial board. Oliver Findl is also a scientific advisor to Carl Zeiss Meditec AG, Croma Pharma GmbH and Johnson & Johnson. SD has also received grant support from Allotex and Johnson & Johnson Vision; is a consultant and/or has received lecture fees from Bausch + Lomb, BVI-PhysIOL, Nidek Inc, Carl Zeiss Meditec, Cristalens, Excel-Lens, Infinite Medical Ventures, Lumenis Vision, Ocuphire Pharma, Oyster Point Pharma, PRN nutraceuticals and ViaLase; and owns equity in Excel-Lens, Infinite Medical Ventures and PRN nutraceuticals.
